A Phase 2 interventional study of Placebo and PF-06649751 in Parkinson Disease, sponsored by Pfizer. Terminated at 37 sites in 4 countries. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.
Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 4th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2016.
This study's enrollment of 57 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 57 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Parkinson Disease by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 15 studies in Parkinson Disease by Pfizer, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 14th registered.
Pfizer’s Parkinson Disease studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing tavapadon in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: PF-06649751
Also known as: oral tablet once daily
Also known as: flexible dose oral tablet once daily
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15
MDS-UPDRS Part III was used to assess the motor signs of Parkinson's disease. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The MDS-UPDRS Part III total score range is 0-132. Higher score indicates more severe motor signs of Parkinson's disease. A negative change from baseline represents an improvement in motor function.
Time frame: Baseline (Day -1/randomization), Week 15
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.
Time frame: From first dose of study treatment up to 28 days after last dose (up to Day 133)
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Following safety laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes); chemistry (blood urea nitrogen/urea and creatinine, glucose , calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein); urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urine bilirubin, urobilinogen, urine creatinine, microscopy, and specific gravity).
Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit
Number of Participants With Vital Signs Data Meeting Categorical Summarization and Orthostatic Hypotension Criteria
Vital signs categorical summarization criteria: 1) supine and standing systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine and standing diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) standing pulse rate \<40 or \>140 bpm; 5) maximum change from baseline (increase or decrease) in supine and standing DBP greater than or equal to (\>=) 20 mmHg; 6) maximum change from baseline (increase or decrease) in supine and standing SBP \>=30 mmHg. Orthostatic hypotension criterion was defined as a decrease of \>=20 mmHg for SBP or \>=10 mmHg for DBP 2 minutes after standing from a supine position.
Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit
Number of Participants Meeting the Categorical Summarization Criteria for Electrocardiogram (ECG) Parameters
ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% increase from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; an increase from baseline of 30 to \<60 msec or \>=60 msec.
Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit
Number of Participants With Worsening and New Onset Suicidality as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Participants with new onset suicidality were those without suicidal ideation and behavior at baseline and reported any suicidal behavior or ideation post-baseline as assessed by C-CASA code mapped from C-SSRS data. Participants with worsening suicidality were those who moved to a lower numbered C-CASA category than was reported at baseline.
Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit
Change From Baseline in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS) Total Score at Days 35, 63, and 105
The QUIP-RS has 4 primary questions pertaining to commonly reported thoughts, urges/desires, and behaviors associated with impulsive-compulsive disorder , each applied to the 4 impulsive-compulsive disorders (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). Each question is anchored with the following 5 responses: Never (0), Rarely (1), Sometimes (2), Often (3), and Very Often (4). The scoring range for each item (ie, disorder) is 0-16. The QUIP-RS total score range is 0-64. Higher score indicates a greater level of the impulsive compulsive disorder.
Time frame: Baseline (Day -1 or randomization); Days 35, 63, 105
Total Physician Withdrawal Checklist (PWC-20) Score
The PWC-20 is a 20-item reliable and sensitive instrument for the assessment of benzodiazepine-like discontinuation symptoms. The total PWC-20 score is the sum of 20 item scores and ranges between 0 and 60. The higher score indicates more frequent/severe symptoms.
Time frame: Day 119
| Milestone | PF-06649751 | Placebo |
|---|---|---|
| Started | 29 | 28 |
| Completed | 25 | 22 |
| Not completed | 4 | 6 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
MDS-UPDRS Part III was used to assess the motor signs of Parkinson's disease. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The MDS-UPDRS Part III total score range is 0-132. Higher score indicates more severe motor signs of Parkinson's disease. A negative change from baseline represents an improvement in motor function.
| units on a scale | PF-06649751 | Placebo |
|---|---|---|
| Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15 | -9.0 ± 1.54 | -4.3 ± 1.65 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.
| Participants | PF-06649751 | Placebo |
|---|---|---|
| AEs | 25 | 18 |
| SAEs | 1 | 0 |
Following safety laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes); chemistry (blood urea nitrogen/urea and creatinine, glucose , calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein); urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urine bilirubin, urobilinogen, urine creatinine, microscopy, and specific gravity).
| Participants | PF-06649751 | Placebo |
|---|---|---|
| Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) | 19 | 19 |
Vital signs categorical summarization criteria: 1) supine and standing systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine and standing diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) standing pulse rate \<40 or \>140 bpm; 5) maximum change from baseline (increase or decrease) in supine and standing DBP greater than or equal to (\>=) 20 mmHg; 6) maximum change from baseline (increase or decrease) in supine and standing SBP \>=30 mmHg. Orthostatic hypotension criterion was defined as a decrease of \>=20 mmHg for SBP or \>=10 mmHg for DBP 2 minutes after standing from a supine position.
| Participants | PF-06649751 | Placebo |
|---|---|---|
| Supine SBP <90 mmHg | 0 | 0 |
| Standing SBP <90 mmHg | 0 | 0 |
| Supine DBP <50 mmHg | 0 | 0 |
| Standing DBP <50 mmHg | 0 | 0 |
| Supine pulse rate <40 bpm | 0 | 0 |
| Supine pulse rate >120 bpm | 0 | 0 |
| Standing pulse rate <40 bpm | 0 | 0 |
| Standing pulse rate >140 bpm | 0 | 0 |
| Maximum increase in standing DBP >=20 mmHg | 0 | 0 |
| Maximum increase in standing SBP >=30 mmHg | 0 | 0 |
| Maximum increase in supine DBP >=20 mmHg | 0 | 1 |
| Maximum increase in supine SBP >=30 mmHg | 0 | 3 |
| Maximum decrease in standing DBP >=20 mmHg | 8 | 2 |
| Maximum decrease in standing SBP >=30 mmHg | 4 | 1 |
| Maximum decrease in supine DBP >=20 mmHg | 9 | 1 |
| Maximum decrease in supine SBP >=30 mmHg | 5 | 0 |
| SBP postural difference(supine-standing) >=20mmHg | 1 | 2 |
| DBP postural difference(supine-standing) >=10mmHg | 3 | 1 |
ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% increase from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; an increase from baseline of 30 to \<60 msec or \>=60 msec.
| Participants | PF-06649751 | Placebo |
|---|---|---|
| PR interval >=300 msec | 0 | 0 |
| QRS duration >=140 msec | 0 | 0 |
| QT interval >=500 msec | 0 | 0 |
| QTcF interval >=450 msec to <480 msec | 0 | 0 |
| QTcF interval >=480 msec to <500 msec | 0 | 0 |
| QTcF interval >=500 msec | 0 | 0 |
| Percent increase in PR interval >=25/50% | 0 | 0 |
| Percent increase in QRS duration >=50% | 0 | 0 |
| Increase in QTcF interval >=30 msec to <60 msec | 1 | 2 |
| Increase in QTcF interval >=60 msec | 0 | 0 |
The C-SSRS is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Participants with new onset suicidality were those without suicidal ideation and behavior at baseline and reported any suicidal behavior or ideation post-baseline as assessed by C-CASA code mapped from C-SSRS data. Participants with worsening suicidality were those who moved to a lower numbered C-CASA category than was reported at baseline.
| Participants | PF-06649751 | Placebo |
|---|---|---|
| Worsening suicidality | 0 | 0 |
| New onset suicidality | 1 | 0 |
The QUIP-RS has 4 primary questions pertaining to commonly reported thoughts, urges/desires, and behaviors associated with impulsive-compulsive disorder , each applied to the 4 impulsive-compulsive disorders (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). Each question is anchored with the following 5 responses: Never (0), Rarely (1), Sometimes (2), Often (3), and Very Often (4). The scoring range for each item (ie, disorder) is 0-16. The QUIP-RS total score range is 0-64. Higher score indicates a greater level of the impulsive compulsive disorder.
| units on a scale | PF-06649751 | Placebo |
|---|---|---|
| Change from baseline at Day 35 | 0.2 ± 5.23 | 1.9 ± 9.49 |
| Change from baseline at Day 63 | -1.1 ± 5.99 | 1.1 ± 9.02 |
| Change from baseline at Day 105 | -1.6 ± 4.54 | -0.2 ± 5.38 |
The PWC-20 is a 20-item reliable and sensitive instrument for the assessment of benzodiazepine-like discontinuation symptoms. The total PWC-20 score is the sum of 20 item scores and ranges between 0 and 60. The higher score indicates more frequent/severe symptoms.
| units on a scale | PF-06649751 | Placebo |
|---|---|---|
| Total Physician Withdrawal Checklist (PWC-20) Score | 1.50 (0 to 12.00) | 1.00 (0 to 11.00) |
Collected over From first dose of study treatment up to 28 days after last dose (up to Day 133). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06649751 | 0/29 (0%) | 1/29 (3.4%) | 22/29 (75.9%) |
| Placebo | 0/28 (0%) | 0/28 (0%) | 12/28 (42.9%) |
| Event | PF-06649751 | Placebo |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 1/29 | 0/28 |
| Event | PF-06649751 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 9/29 | 2/28 |
| HeadacheNervous system disorders | 7/29 | 2/28 |
| Dry mouthGastrointestinal disorders | 5/29 | 0/28 |
| SomnolenceNervous system disorders | 4/29 | 1/28 |
| TremorNervous system disorders | 4/29 | 2/28 |
| FatigueGeneral disorders | 3/29 | 3/28 |
| DiarrhoeaGastrointestinal disorders | 1/29 | 3/28 |
| Decreased appetiteMetabolism and nutrition disorders | 3/29 | 0/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/29 | 0/28 |
| Hot flushVascular disorders | 3/29 | 0/28 |
All participants who received at least 1 dose of study treatment (PF-06649751 or placebo).
| Age, Continuous(years) | PF-06649751 | Placebo | Total |
|---|---|---|---|
| Mean | 64.76 ± 8.34 | 63.36 ± 9.16 | 64.07 ± 8.71 |
| Sex: Female, Male(Participants) | PF-06649751 | Placebo | Total |
|---|---|---|---|
| Female | 9 | 14 | 23 |
| Male | 20 | 14 | 34 |
| Ethnicity (NIH/OMB)(Participants) | PF-06649751 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 27 | 27 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PF-06649751 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 28 | 25 | 53 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2016 to primary completion in Jan 2018, 15 months.
Results were first posted in Jan 2019, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tavapadon